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CASE 5m1996 
Thrombosis After the Use of a Heparin-Coated 
Cardiopulmonary Bypass Circuit in a Patient With 
Heparin-Induced Thrombocytopenia 
Michel J. Van Dyck, MD, Edith Lavenne-Pardonge, MD, 
Marie-Agn6s Azerad, MD, Amine G. Matta, MD, 
Maurice Moriau, MD, and Mark E. Comunale, MD 
Case Presentatton 
A 64-year-old, 165-cm, 58-kg woman was admitted to the 
hospital with an inferior myocardial infarction. She under- 
went an emergent percutaneous transluminal coronary 
angioplasty (PTCA) complicated by an early reocclusion 
necessitating a second PTCA. The second PTCA compli- 
cated itself by the dissection of the right coronary artery 
(RCA), necessitating the placement of four stents in the 
RCA. The patient was then treated with porcine heparin 
(H) for 7 days. Warfarin was progressively titrated to a 
prothrombin time of 23% (international normalized ra- 
tio = 3.8), and heparin was then stopped. After 3 days of 
effectwe warfarin treatment, she suddenly developed cardio- 
genic shock with third-degree atrioventricular block, neces- 
sitating resuscitation maneuvers, intubation, placement of 
an intra-aortic balloon pump, and a pacemaker. After this 
resuscitation, she recovered well except for a right hemipa- 
resis that was attributed to a prolonged hypotensive state. 
Coronary angiography disclosed a reocclusion of the RCA. 
Fibrinolytic therapy was then administered, and a continu- 
ous infusion of heparin was reintroduced. Forty-eight hours 
after her ischemic event, a cerebral computed tomography 
(CT) scan was normal, and she had no neurologic sequelae. 
Nine days later, despite receiving a continuous infusion of 
heparin, she became ischemic in the right coronary artery 
territory, and an emergent coronary revascularization was 
planned. 
While evaluating the patient's files, the attending anesthe- 
siologist found that the platelet level was below 35,000/mm 3 
from the beginning of the second heparin administration 10 
days earlier (Fig 1), and he suspected a syndrome of 
heparin-induced thrombocytopenia (HIT). Because of the 
presence of four stents in the patient's RCA and owing to 
her history of the repetitive coronary occlusions, the cardi- 
ologists refused to stop the heparin infusion. This infusion 
was therefore stopped in the operating room. A central 
venous catheter was already in place, a radial arterial 
catheter was then placed under local anesthesia, nd both 
were flushed with 0.9% saline without heparin. Anesthesia 
was induced with etomidate and sufentanil, and muscle 
paralysis achieved with pancuronium. Anesthesia was main- 
tained with midazolam, and a continuous infusion of 
sufentanil, 2 Ixg/kg/hr. 
Iloprost is not available in Belgium; neither are the 
heparin substitutes proposed in the literature. The anesthe- 
siologist had no experience with the use of low-molecular- 
weight heparin (LMWH) during bypass. Therefore, he 
elected to use a heparin-coated cardiopulmonary bypass 
(CPB) circuit (HC-CPB) (Durafio II; Bentley [Englewood, 
CO], because of its theoretical advantages ofbiocompatibil- 
ity and protection of platelets against activation caused by 
contact with the artificial surfaces. Only 50 IU/kg of 
porcine heparin were administered in place of the usual 300 
IU/kg. Two saphenous grafts were sutured on the RCA. 
The procedure was performed under normothermia nd 
intermittent antegrade warm blood cardioplegia. Aortic cross- 
clamp time was 34 minutes, and CPB lasted 55 minutes. No 
pharmacologic support was needed to come off bypass. 
The platelet level was 34,000/mm 3 before surgery and 
39,000/mm 3 after 50 IU/kg of H. It decreased to 22,000/ 
mm 3 after 7 minutes of CPB, possibly because of hemodilu- 
tion, and returned to 39,000/mm 3 after discontinuation of 
CPB. Activated coagulation times with kaolin (ACT) (He- 
motec; Medtronic [Uden, The Netherlands]) were 151 
seconds before heparin administration, 231 seconds after 
50 IU/kg of H, 445 and 443 seconds during CPB, and 295 
seconds after CPB. Only 10 mg (2,000 IU) of protamine 
were then administered, and ACT returned to 148 seconds 
(Fig 2). 
After administration of another 1,000 IU of protamine, 
the ACT was 82 seconds. Despite this, the patient was still 
bleeding actwely. It was then judged that no more heparin 
was circulating at that time, and it was decided that it would 
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Fig 1. Course of the platelet 
count versus hospital stay. PTCA, 
percutaneous translummal coro- 
nary angioplasty; TIA, transient 
cerebral ischemic attack, CPB, 
cardiopulmonary bypass; DVT, 
deep venous thrombosis. 
be safe to admlmster 6 units of platelet concentrate. All the 
blood lost during the procedure was processed (Cobe-IBM 
2991, Lakewood, CO) and readministered to the patient: It 
constituted a volume of 650 mL of erythrocytes concen- 
trate. 
The patient was admitted to the intensive care unit 
(ICU) and there, because of continuous bleeding, received 
6 more umts of platelet concentrate. This administration 
stopped the bleeding, and the platelet count at that Ume 
was 83,000/ram 3. Judged empirically as being safe, nadopa- 
rln and aspirin therapy were begun on the second postopera- 
tive day. The patient left the ICU on the second postopera- 
Uve day, and from that moment her platelet count 
continuously improved up to normal values (Fig 1). Unfor- 
tunately, on the third postoperative day, the patient devel- 
oped swelling of both inferior limbs. A pelvic CT scan 
disclosed an extensive thrombosis of her two lhac veins and 
the inferior vena cava up to the renal veins. Despite 
addition of warfarin to the therapy, only a partial resolution 
was obtained 25 days later. 
She left the hospital on the 30th postoperatwe day, 49 
days after her admission, under effective warfarin anticoagu- 
lation and without neurologic deficit. 
DISCUSSION 
HIT is a syndrome in which thrombocytopenia, some- 
times accompanied by thrombosis, develops after 5 or more 
days of heparm therapy. Although type I is a direct 
aggregating effect of heparin on platelets, type-II HIT is an 
immunologic reaction, revolving immunoglobulin G (IgG). 
These antibodms bind to the antigenic omplex formed by 
heparin and platelet factor-4 (H/PF4), and, in turn, acti- 
vate the platelets through thor Fc receptors. 1-4 This syn- 
drome is a challenge for the cardiac anesthesiologist be- 
cause it can be precipitated by the heparin used during 
CPBfi -7 It can also occur after surgery, 8 9 and in 20% of the 
cases is assocaated w~th arterial or venous thrombosis 
leading to severe morbidity. Several strategies to prevent or 
minimize its occurrence have been proposed including the 
following: blockade of platelet activation by aspmn, dlpyri- 
damole, or iloprost before heparin admmlstrationT,1°-12; 
Fig 2 Evolution of the intra- 
operative ACT and platelet count 
1, before CPB; 2, after heparin, 
3,000 IU, 3, 10 minutes CPB, 4, 35 
minutes CPB, 5, after CPB, 6, 
after protamine, 2,000 IU; 7, after 
protamine, 1,000 IU; 8. after 12 
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plasmapheresis before surgeryl3; substitution of ancrod, ~4,Is 
hirudin, 16 or heparinoids I7 for heparin; or use of LMWHfi  ,I9 
HC-CPB prevents blood from clotting when it contacts 
the artificial surfaces and can reduce the degree of paren- 
teral anticoagulation required for CPB, reduce comple- 
ment activation, and simultaneously protect platelets from 
deterioration. 20-22 
Recent progress has been made in the understanding and 
management of the HIT syndrome. 1-4 This entity has been 
divided into two types: Type I, the most frequent, is mild, of 
early onset, and reversible despite continuation of heparin. 
It is not associated with thrombosis and appears related to a 
direct pro-aggregant effect of heparin binding on platelets. 
Type II affects 0.1% to 3% of patients on heparin, is caused 
by an immunologic mechanism, and is often associated with 
severe venous or arterial thrombosis. 23IgG binds to the 
antigenic omplex formed by heparin and H/PF4, and, in 
turn, activates the platelets through their Fc receptors. I-4
Thrombocytopenia occurs within 5 to 15 days of heparin 
therapy and can occur earlier if sensitization with heparin 
already exists (Table 1). The antibodies could also react 
with endothelial cells and possibly provoke an immunologic 
vascular injury that could predispose the patient o throm- 
bosis.i, 23 
Some tests have been described to confirm the diagnosis 
of HIT. 6 The platelet aggregation test is highly specific but 
poorly sensitive with a high incidence of false-positive 
tests. 24 *14C-SerotonIn release assays are both sensitive and 
specific but difficult to perform, as Only an enzyme-linked 
immunosorbent assay (ELISA) test with heparin and PF4 
reacting with IgG from the serum of susceptible patients 
could confirm the diagnosis, but ELISA is not performed by 
all laboratories. 4 
This patient appears to have first presented a type-I HIT 
with a transient decrease of her platelet count from 278,000 
to 177,000/mm 3 (Fig 1). Then, after a 3-day interruption of 
treatment, he reintroduction of heparin immediately pro- 
voked a catastrophic decrease of her platelet level to 
34,000/mm 3, evocative of a type-II HIT. She thereafter 
presented with postoperative thrombosis of her inferior 
vena cava and iliac and femoral veins. The transient 
cerebral ischemic attack that she sustained may not have 
been a thrombotic omplication of HIT. At that time, she 
had not yet resumed recelwng heparin, and thrombocytope- 
nia was not present. Owing to its emergent nature, this case 
raises ome important concerns. 
Table 1. Characteristics of Type I and Type II HIT 
Type I Type II 
Frequent 
Mild (> 100,000 platelets) 
Early ( < 5 days) 
Without thrombosm 
Reversible during heparm 
admm,stratlon 
Pro-aggregant effect of heparm 
on platelets 
Rare 
Severe ( < 35,000 platelets) 
5-15 days 
Assoctated w,th thromboms 
Reversible with heparm discon- 
tinuation 
Immunologm react=on, IgG 
binding to H/PF4 complex 
Abbrevlatfons IgG, ,mmunoglobuhn G; H/PF4, heparm/platelet fac- 
tor 4 
1. Heparin should have been stopped as soon as the 
diagnosis was suspected. 6 The cardiologists refused to make 
this decision because of the expected risk of right coronary 
artery thrombosis at the level of the intraluminal stents. 
The heparin infusion was stopped in the operating room, 
and no heparin was added to the arterial flush. A single 
bolus dose of 50 IU/kg administered before the CPB was 
the only heparin source. 
2. Plasmapheresis could have been performed preopera- 
tively. This therapy could reduce or remove the offending 
antibodies from circulation ~3 but reqmres daily apheresis 
for at least 2 to 3 days preoperatively to obtain normaliza- 
tion of the platelet count. 
3. The heparin-coated CPB circuit should not have been 
used. Thrombocytopema h s been described, associated 
with the use of heparin-coated catheters. 26,27 Such catheters 
are coated with a heparln-benzalkonium chloride complex, s 
Elution of heparin from these catheters has been demon- 
strated. 27 Even this slow release of heparln could be 
sufficient o cause thrombocytopenia in patients with anti- 
H/PF4 antibodies. 27This patient had a triple-lumen cath- 
eter in place (Arrow [Reading, PA]) that was not heparin- 
coated. No pulmonary artery catheter was inserted. 
HC-CPBs have some advantages over conventional un- 
coated circuits, all of them accounting for an increased 
biocompatibility. The artificial surfaces are less thrombo- 
gemc; the inflammatory response to CPB is reduced; and 
the platelets undergo less activation and functional deterio- 
ration. 2°-22 Two main types of HC-CPB circuits are manufac- 
tured: Duraflo II (Bentley) and Carmeda CBAS (Medtronlc). 
In the first type of circuit, the tubing is coated with 
unfractionated porcine heparin, whereas in the second, it is 
coated with a fractlonated heparin. The mode of binding of 
heparin in these circuits is different from the heparln- 
benzalkonlum complex used on the pulmonary artery cath- 
eters and is also different in each of the two circuits. An 
Ionic binding is used in the Duraflo II, and a covalent 
end-point attachment is used in the CBAS. The latter 
appears to account for a more stable heparin attachment s 
with less release and more available active binding sites for 
antithrombin III The CBAS circuit could therefore be the 
better choice and has been successfully used, along with 
LMWH, in one case of HIT. 2s Because of the emergency 
nature of the case and the availability of the circuits, the 
authors' choice was limited to a conventional circuit with 
full-dose (300 IU/kg) heparln or a Duraflo II circuit. They 
relied on a Duraflo circuit, and used low-dose porcine 
heparin (50 IU/kg). yon Segesser 29 showed that when 
HC-CPB is conducted without systemic heparinization, 
clotting could occur in the zones of stagnation of blood and 
during the phases of low pump flow. Because this patient 
received 3,000 IU of heparin (50 IU/kg) and some heparln 
could have been released from the tubings during the 
bypass, this small amount may have been sufficient to 
aggravate the Immunologic reaction, and hence the throm- 
bocytopenia nd the development of the postoperative 
deep venous thrombosis. 
4. A heparin substitute should have been used. Some 
molecules are under clinical trial: dermatan sulfate, Orga- 
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ran (Nourypharma, The Netherlands), ancrod, and hlrudln 
(Table 2). Recombinant-hlrudm is a potent hrombin inhibi- 
tor and has been used as the anticoagulant for cardmc 
operations ~6,3° and as a treatment for deep venous thrombo- 
sis. 31 It has a short half-life in patients with normal renal 
function, and its effect could be monitored by means of 
activated partial thromboplastin time (aPTT) and ACT. 
However, r-hirudin has been found less effective than 
heparin in suppressing thrombm formation and fibrinopep- 
tlde-A production. 32No antagomst is available. 
Ancrod is a defibrinogenating enzyme purified from 
viper's venom. It selectively cleaves fibrmopeptide A and 
has been used as an alternate method of ant!coagulation 
during CPB in HIT patientsJ 4,15 Its infusion should be 
begun 12 hours preoperatively, and fibrinogen levels should 
be measured repetitwely. Cryoprecipitates can be adminis- 
tered at the end of the surgery to reverse the effects of 
ancrod. 
Heparinoids like dermatan 33and Orgaran (danaparoid 
sodium) 17 could be promising in such cases. Both of them 
have been used during CPB instead of heparin. Orgaran Is 
said to have good antithrombotic a tivity with only mimmal 
bleeding-enhancing activity and no effect on platelet func- 
tion. 
5. Use of LMWH during CPB has been proposed 18J9 and 
also used as an alternative to unfractionated heparin for 
urgent surgery. 34-38 However, even if patients receiving 
LMWH appear to have a lower incidence of thrombocytope- 
nia, thrombosis, and antibody formation than those recew- 
ing standard heparin, 39 some cases of HIT have been 
described with the use of LMWH, possibly caused by some 
cross-reactivity with the heparin-dependent antibodies. 5,6 
Moreover, biologic tests are insufficient to guide the thera- 
peutics, and protamine has only a slight antagomstic effect. 
The authors relied on nadroparin (Fraxiparin [Sanofi- 
Winthrop, Bondeville, France] 0.6 mL BID) for the treat- 
ment of the postoperative thrombosis in the present pa- 
tient. This, along with concomitant wafarin therapy and 
heparm discontinuation, allowed restoration of the ptatelet 
count to normal values m 3 days (Fig 1). In retrospect, it
would have been judicious to test the absence of cross- 
reactivity by aggregation tests before its administration. 
6. The platelets should have been protected with ilo- 
prost, aspmn, or dipyridamole 7 before conventional CPB 
under a full dose of unfractionated heparin. This patient 
had not received aspirin for the last 10 preoperative days, 
and therefore a protective ffect could not be expected. 
Successful use of the prostacychn analog iloprost has often 
been described] °,11 but this drug was not available. Prosta- 
glandin I2 (PGIa) does not seem to be as effective as iloprost 
m contrast o prostaglandln E2 that has been used as a 
substituteJ 2 However, these three drugs cause profound 
hypotension necessitating the concomitant infusion of vaso- 
pressors. 
7. Platelets should not have been administered after 
protamine administration: They could have acted hke "oil 
on the fire" and have been responsible for the observed 
postoperative thrombbsis. However, their administration 
was deemed necessary because of continuing bleeding after 
protamine administration despite normalization of the 
ACT. Moreover? they were administered only after com- 
plete heparin reversal with protamine; therefore, no more 
heparin was circulating to form an immune complex able to 
react with the patient's IgG. Recently, Boshkov et al found 
a strong association between venous thrombosis and recent 
surgery of any type. a3 They considered HIT syndrome as a 
procoagulant disorder able to provoke thrombosis at sites 
of preexisting vascular pathology. The observed venous 
thrombosis can be either the consequence of the surgery or 
a complication of a low output gtate with venous tasis, as 
well as the consequence of the platelet infusion itself. 
8. Immunoglobulins should have been administered post- 
operatively. Their administration has been described in 
HIT, along with platelet ransfusion, based on their efficacy 
in restoring platelet count in immune thrombocytopemc 
purpura. 4° In these two syndromes , immunoglobulin possi- 
bly works by blocking the Fc receptor. 
COMMENTARY* 
The case presented illustrates many of the typical manage- 
ment problems associated with patients diagnosed with 
HIT who are undergoing surgery requiring heparinization. 
First, the question of how the diagnosis of HIT was made 
and in fact whether the patient has HIT should be ascer- 
tained. The diagnosis of HIT may be obscured by the 
presence of other medical conditions or medications that 
may cause thrombocytopenia. Often, as presented in this 
case, laboratory tests such as 14C-serotonin release assay 
and heparin/PF4-IgG ELISA are simply not available, and 
clinical presentation is the sole basis for diagnosis. Either a 
decrease in platelet count of 30% of preheparin level or an 
unexpected thromboembolic event in a patient receiving 
heparln warrants consideration of the diagnosis of HIT. 
*Mark E Comunale, MD 
Table 2. Comparison of Heparin Substitutes for Use as Anticoagulants During CPB 
LMWH Htrudm Ancrod Dermatan 
Availability (+) (-)  (-)  (-)  
Onset Immediate Immedtate 12 h Immediate 
Tests of efficacy Ant~ Xa acttvtty TT, PT, APTT Plasma fibrmogen concentratton Antt-ila activity, anti-Xa activtty 
ACT ?-APTT 
Anttdote (Protamine) (-)  Cryoprecipltate (-)  
Duration of actton 24 h 30 mm 40 mm 
Abbrevtattons' LMWH, Iow-molecular-wetght heparm; ACT, activated coagulation t~me; APPT, actwated parttal thromboplastm time; PT, 
prothrombin time, TT, thrombin ttme 
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Sheridan et a125 have classified the likelihood of HIT based 
on the clinical setting. If thrombocytopenia develops in a 
patient receiving heparin and other causes are excluded, if 
thrombocytopenia recurs on challenge with heparin, or if 
acute arterial thrombosis occurs in the absence Of other 
thrombotic factors, a diagnosis of "definite" HIT is made. 
The likelihood is designated "probable" if thrombocytope- 
nia occurs in a patient receiving heparin and other causes 
are excluded; "possible" if these two criteria are present 
but the thrombocytopenia either resolves with continued 
heparin administration or fails to recur with a heparin 
challenge; or "unlikely" if another cause of thrombocytope- 
nia is found or it fails to resolve on discontinuing the 
heparin. 
Criteria that may also be present when the diagnosis of 
HIT is made are shown in Table 3. However, these criteria 
are not necessarily all met before the diagnosis is made. An 
abrupt decline in platelet concentration on reexposure to 
heparin as occurred in this case strongly supports the 
diagnosis of HIT. However, it should be noted that HIT can 
occur in the absence of a decrease lri platelet count, 41 and 
occasionally, an unexpected thromboembolic event in a 
patient receiving heparin may be the first sign of HIT. In 
light of this, it is tempting to speculate that the cause of the 
patient's ischemia may have been heparin-induced platelet 
aggregation i the right coronary artery distribution. 
Once the diagnosis has been established, choosing an 
appropriate management plan can be a challenge. As in 
many immune-mediated diseases, the presence of even 
trace amounts of antigen or antigen/hapten may be capable 
of inducing imniunoglobulin-mediated r actions. There- 
fore, all hep~iriii administration should be discontinued 
including the use of subcutaneous heparin. Saline should be 
substituted for heparin in pressure monitoring tubing and 
intravenous flush solutions, and heparin-bonded catheters 
should be removed. 
If surgery requiring the use of heparin is not urgent, it 
should be postponed. Discontinuing heparin will result In a 
decrease in heparln-dependent a iplatelet antibodies over 
several weeks. Unfortunately, it is not possible to reliably 
predict how long antiplatelet antibodies will remain in the 
circulation. Patients rechallenged with heparln up to 2 
months after recovery have become thrombocytopenlc. 42 
Interestingly, although plasma heparin-dependent IgG di- 
minishes rapidly over 2 months after cessation of heparin 
exposure, platelets of sensitized patients are still capable of 
activation and aggregation, suggesting a major portion of 
the heparin-dependent a ibody may be membrane bound. 42 
Table 3, Crtterla That Are Usually Present When a D=agnosis 
of HIT Is Made 
1 The patmnt was not thrombocytopenm before heparm admmts- 
trat~on 
2 A platelet count of less than 150,000/~L is determined on two 
separate occasions 24 hours apart during heparm therapy 
3 Other causes of thrombocytopema re excluded 
4 A thrornbotm event (venous or arterial) distract from that for 
which the heparm was administered occurs 2 or more days after 
m~tmtion of heparin administration. 
In vitro tests of heparln-induced platelet aggregation and 
activation should follow and will gradually become nega- 
tive. 43 Several patients in whom surgery was delayed until 
platelet aggregation studies were negative underwent un- 
eventful heparlnization and CPB. 43 
When surgery cannot be postponed as in this case, the 
choice of management is between the use of heparin with 
concomitant administration ofagents that prevent heparln- 
induced platelet activation (for example iloprost, a PGI2 
analog, or PGEI), LMWH preparations, ancrod, or other 
nonheparln anticoagulation agents 
The authors' use of a heparin-bonded CPB circuit is a 
novel approach, and they are to be congratulated on their 
creativity in a desperate circumstance. However, it also 
raises important concerns. Although the use of heparin- 
bonded CPB circuits has been shown to produce better 
platelet preservation, 44 the presence of a heparln-depen- 
dent IgG in patients with HIT complicates the scenario. 
The Duraflo II CPB circuit is manufactured by a process 
called "universal bonding" whereby unfractionated heparln 
molecules are modified and attached to the circuit using a 
proprietary formulation. 45Although the stability of the 
heparin bonding on the Duraflo II circuit is superior to 
other heparin-bonded circuits, leaching of bound heparin 
from the circmt into the circulation still occurs 45 and could 
precipitate platelet activation and aggregation i patients 
with HIT. It is also likely that heparin that is bound on the 
circuit can interact with PF4 to form the reactive antigen on 
the platelet surface. The presence of a heparm-dependent 
IgG in patients with HIT would allow binding of this 
complex with subsequent activation of platelets. Perhaps 
even more important, systemic heparin administration is
still required when using a heparin-bonded CPB circuit. 
Fifty IU heparin/kg is very hkely to precipitate HIT in 
susceptible patients with specific IgG. 
The early postoperative bleeding and extensive thrombo- 
sis that occurred in the patient presented is not an unex- 
pected outcome in patients with HIT who are exposed to 
heparin without he concomitant use of agents that prevent 
platelet activation. This unfortunate outcome might have 
been prevented by the concomitant use of prostaglandln E1 
from immediately after induction of anesthesia through 
heparin neutralization and chest closure. PGEb like PGI2, 
inhibits platelet activation and aggregation by increasing 
intracellular concentrations of platelet cyclic adenosine 
monophosphate. 46 Hypotension associated with the use of 
prostaglandins can be prevented by simultaneous infusion 
of vasopressors such as phenylephrine. 
Alternatively, the use of other management pathways 
such as ancrod, LMWHs, antiplatelet agents, or hirudin can 
be considered. Unfortunately, some of these agents may be 
unavailable (hlrudin), are of limited efficacy (LMWH, 
antiplatelet agents), or are associated with severe adverse 
side effects (ancrod). The small number of patients present- 
mg with HIT has also contributed to the lack of controlled 
trials in this area. In fact, iloprost, one of the most 
promising agents for managing patients with HIT, was 
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denied approval by the Food and Drug Administration 
citing lack of control trials (personal communication, Ber- 
lex Laboratories, Wayne, N J). 
Argatroban, a small molecular direct thrombin inhibitor 
that rapidly, selectively, and reversibly binds the catalytic 
site of thrombin, is currently undergoing clinical trials and 
may be available soon for the management of patients with 
H ITS  
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